RxDoctor Payments Data

Rachael Ofili, NP

Primary Care · Newark, DENPI 1194498014

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations.

$2,257in general payments, 2019–2025

Across 122 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$339
  • Novo Nordisk$288
  • AbbVie$266
  • AstraZeneca$260
  • Teva Pharmaceuticals USA, Inc.$130
  • Amgen$122
  • plus $851 from 23 others

What the payments were for

  • Food & beverage$2,257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,257 in reported general payments places this provider in the 80th percentile of 25 primary care providers in Delaware.

See all primary care providers in Delaware

Medicare billing

Part B allowed, 2024
$23,764
Medicare patients
174
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rosuvastatin Calcium54$996
Omeprazole38$754
Atorvastatin Calcium52$611
Amlodipine-ValsartanAmlodipine Besylate/Valsartan14$482
Glimepiride17$452
Amlodipine Besylate51$363
Levothyroxine Sodium19$294
Gabapentin13$292
Metformin Hcl43$267
Pravastatin Sodium17$214
Losartan Potassium24$190
Carvedilol16$187
Lisinopril21$130
Montelukast Sodium11$99
Escitalopram Oxalate12$88

Paid to pharmacies, not to this prescriber.

Other primary care in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →